Shawn Ritchie, CEO and CSO, and Tara Smith, VP Therapeutics, will be in Barcelona to present updates on the MLD’s clinical development program for Rhizomelic Chondrodysplasia Punctata (RCDP). For more information on RCDP and the trial click here. More information on the conference is here.
